Surface-modified functionalized polycaprolactone scaffolds for bone repair: in vitro and in vivo experiments.

A porcine calvaria defect study was carried out to investigate the bone repair potential of three-dimensional (3D)-printed poly-ε-caprolactone (PCL) scaffolds embedded with nanoporous PCL. A microscopic grid network was created by rapid prototyping making a 3D-fused deposition model (FDM-PCL). Afterward, the FDM-PCL scaffolds were infused with a mixture of PCL, water, and 1,4-dioxane and underwent a thermal-induced phase separation (TIPS) followed by lyophilization. The TIPS process lead to a nanoporous structure shielded by the printed microstructure (NSP-PCL). Sixteen Landrace pigs were divided into two groups with 8 and 12 weeks follow-up, respectively. A total of six nonpenetrating holes were drilled in the calvaria of each animal. The size of the cylindrical defects was h 10 mm and Ø 10 mm. The defects were distributed randomly using following groups: (a) NSP-PCL scaffold, (b) FDM-PCL scaffold, (c) autograft, (d) empty defect, (a1) NSP-PCL scaffold + autologous mononuclear cells, and (a2) NSP-PCL scaffold + bone morphogenetic protein 2. Bone volume to total volume was analyzed using microcomputed tomography (µCT) and histomorphometry. The µCT and histological data showed significantly less bone formation in the NSP-PCL scaffolds in all three variations after both 8 and 12 weeks compared to all other groups. The positive autograft control had significantly higher new bone formation compared to all other groups except the FDM-PCL when analyzed using histomorphometry. The NSP-PCL scaffolds were heavily infiltrated with foreign body giant cells suggesting an inflammatory response and perhaps active resorption of the scaffold material. The unmodified FDM-PCL scaffold showed good osteoconductivity and osseointegration after both 8 and 12 weeks.

[1]  Antonios G Mikos,et al.  Biomimetic materials for tissue engineering. , 2003, Biomaterials.

[2]  K. Chihara,et al.  Stimulatory effect of bone morphogenetic protein‐2 on osteoclast‐like cell formation and bone‐resorbing activity , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  K. Yamato,et al.  Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. , 1999, Biochemical and biophysical research communications.

[4]  H. Takita,et al.  Geometry of Carriers Controlling Phenotypic Expression in BMP-Induced Osteogenesis and Chondrogenesis , 2001, The Journal of bone and joint surgery. American volume.

[5]  J. Westendorf,et al.  Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors , 2010, Journal of cellular biochemistry.

[6]  L. Bjursten,et al.  Pore size in implanted polypropylene filters is critical for tissue organization. , 2003, Journal of biomedical materials research. Part A.

[7]  S F Hulbert,et al.  Potential of ceramic materials as permanently implantable skeletal prostheses. , 1970, Journal of biomedical materials research.

[8]  T. Lim,et al.  Repair of calvarial defects with customized tissue-engineered bone grafts I. Evaluation of osteogenesis in a three-dimensional culture system. , 2003, Tissue engineering.

[9]  Y. Shiozawa,et al.  Erythropoietin modulates the structure of bone morphogenetic protein 2-engineered cranial bone. , 2012, Tissue engineering. Part A.

[10]  V. Barron,et al.  Fabrication, mechanical and in vivo performance of polycaprolactone/tricalcium phosphate composite scaffolds. , 2012, Acta biomaterialia.

[11]  A. Göpferich,et al.  Mechanisms of polymer degradation and erosion. , 1996, Biomaterials.

[12]  Hyeongjin Lee,et al.  Three-dimensional plotted PCL/β-TCP scaffolds coated with a collagen layer: preparation, physical properties and in vitro evaluation for bone tissue regeneration , 2011 .

[13]  A. Göpferich,et al.  Why degradable polymers undergo surface erosion or bulk erosion. , 2002, Biomaterials.

[14]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[15]  K. Schlegel,et al.  The monocortical critical size bone defect as an alternative experimental model in testing bone substitute materials. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[16]  Moustapha Kassem,et al.  Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. , 2007, Biomaterials.

[17]  A. Boccaccini,et al.  Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. , 2006, Biomaterials.

[18]  David Williams,et al.  Benefit and risk in tissue engineering , 2004 .

[19]  M. Casal,et al.  Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery) , 2008, Journal of tissue engineering and regenerative medicine.

[20]  Jin Man Kim,et al.  In vitro and in vivo characteristics of PCL scaffolds with pore size gradient fabricated by a centrifugation method. , 2007, Biomaterials.

[21]  G L Kimmel,et al.  Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (epsilon-caprolactone), and their copolymers in vivo. , 1981, Biomaterials.

[22]  S C Woodward,et al.  The intracellular degradation of poly(epsilon-caprolactone). , 1985, Journal of biomedical materials research.

[23]  R L Reis,et al.  Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts) , 2008, Journal of tissue engineering and regenerative medicine.

[24]  P. Supaphol,et al.  Polycaprolactone/hydroxyapatite composite scaffolds: preparation, characterization, and in vitro and in vivo biological responses of human primary bone cells. , 2010, Journal of biomedical materials research. Part A.

[25]  Francesca Ungaro,et al.  Controlled drug delivery in tissue engineering. , 2008, Advanced drug delivery reviews.

[26]  Swee Hin Teoh,et al.  Evaluation of polycaprolactone scaffold degradation for 6 months in vitro and in vivo. , 2009, Journal of biomedical materials research. Part A.

[27]  D. Williams,et al.  Mechanisms of polymer degradation in implantable devices. I. Poly(caprolactone). , 1993, Biomaterials.

[28]  Brian Derby,et al.  Printing and Prototyping of Tissues and Scaffolds , 2012, Science.

[29]  A. Göpferich,et al.  Biomimetic polymers in pharmaceutical and biomedical sciences. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  Yoshinori Kuboki,et al.  Geometry of Artificial ECM: Sizes of Pores Controlling Phenotype Expression in BMP-Induced Osteogenesis and Chondrogenesis , 2002, Connective tissue research.

[31]  J. Goldner.  A modification of the masson trichrome technique for routine laboratory purposes. , 1938, The American journal of pathology.

[32]  T. Jensen,et al.  Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells , 2002, Nature Biotechnology.

[33]  M. Kassem,et al.  Assessment of bone formation capacity using in vivo transplantation assays: procedure and tissue analysis. , 2008, Methods in molecular biology.

[34]  D. Kaplan,et al.  Porosity of 3D biomaterial scaffolds and osteogenesis. , 2005, Biomaterials.

[35]  Swee Hin Teoh,et al.  Cranioplasty after Trephination using a Novel Biodegradable Burr Hole Cover: Technical Case Report , 2006, Neurosurgery.

[36]  M. Kassem,et al.  Flow perfusion culture of human mesenchymal stem cells on coralline hydroxyapatite scaffolds with various pore sizes. , 2011, Journal of biomedical materials research. Part A.

[37]  M. Lind,et al.  A novel nano-structured porous polycaprolactone scaffold improves hyaline cartilage repair in a rabbit model compared to a collagen type I/III scaffold: in vitro and in vivo studies , 2012, Knee Surgery, Sports Traumatology, Arthroscopy.